← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Sphingosine-1-phosphate (S1P) receptor modulators
etrasimod
L04AE05
Forms & Strengths
- 0.5mg, 1mg capsules
- Film-coated
- For oral administration
Adult Dosing
- Initial dose: 0.5mg once daily
- Maintenance dose: 1mg once daily after 30 days
- Maximum dose: 1mg once daily
Pediatric Dosing
- Not established for patients under 18 years
- Use in pediatric patients not recommended
Indications
- Moderately to severely active ulcerative colitis
- Active psoriatic arthritis
- Moderate to severe Crohn’s disease
Mechanism of Action
- S1P receptor modulator
- Selectively binds to S1P1 and S1P4 receptors
- Reduces lymphocyte count in the blood
Contraindications
- History of serious allergic reaction to etrasimod
- Active, severe or uncontrolled infections
- CYP2C9 poor metabolizers, consider alternative therapy
Adverse Reactions
- Headache
- Nausea
- Upper respiratory infection
- Increased liver transaminases
- Lymphopenia
Drug Interactions
- Avoid concomitant use with S1P modulators
- Monitor with immunosuppressants and CYP3A4 inhibitors
- Increased risk of adverse effects with ketoconazole and cyclosporine
Curated Content: Needs Vetting Before Put to Clinical Use